Five Prime Announces Second Quarter 2016 Results and Provides Business Update
04 août 2016 16h05 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Therapeutics to Announce Second Quarter 2016 Financial Results and Host Conference Call on August 4
18 juil. 2016 16h05 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., July 18, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
GSK Exclusively Licenses Intellectual Property for Respiratory Disease Target Identified Using Five Prime’s Proprietary Protein Discovery Platform
14 juil. 2016 17h00 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., July 14, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Therapeutics Receives FDA Orphan Drug Designation for FPA144 for the Treatment of Gastric Cancer
05 juil. 2016 09h25 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., July 05, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Therapeutics to Use Proprietary Protein Discovery Platform to Identify New Factors that Generate Hematopoietic Stem Cells in Collaboration with the University of Minnesota Medical School
27 juin 2016 09h25 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., June 27, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Therapeutics Presents Updated Data from Phase 1 trial of Single-Agent FPA144 at 2016 ASCO Annual Meeting
06 juin 2016 09h25 HE
|
Five Prime Therapeutics, Inc.
Initial data show a 33% confirmed objective response rate, 77% disease control rate, and 12-week progression free survival of 67% in 9 FGFR2b+ gastric cancer patients available for...
Five Prime Therapeutics Announces Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 Presented at 2016 ASCO Annual Meeting
04 juin 2016 09h24 HE
|
Five Prime Therapeutics, Inc.
Objective response rate of 39% and disease control rate of 100% in patients at or below the maximum tolerated dose level; progression free survival of 6.8 months, though data are still maturingThere...
Five Prime Therapeutics to Present at the Jefferies 2016 Healthcare Conference
02 juin 2016 09h30 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., June 02, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and...
Five Prime Therapeutics Appoints Dr. Robert Sikorski as Chief Medical Officer
01 juin 2016 16h05 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., June 01, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Therapeutics Announces Updated Clinical Data on FPA144 and FP-1039 to be Presented during 2016 ASCO Annual Meeting
18 mai 2016 17h00 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 18, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...